3 ms·
It's a two part story: they work. The second part is the bad part: they work so well that diabetics who actually need them can struggle to find stocks. I tend
by ggm 4y ago
It's a two part story: they work.
The second part is the bad part: they work so well that diabetics who actually need them can struggle to find stocks.
I tend to think that meds like these should stop being IPR a lot sooner. They are going to all sell for a long long time. Instead of an immediate ROI on the undoubtedly heinous development R&D costs they should be a 50+ year money stream at a lower profit rate, or preferably none.
This is also why I think state funded drug development is needed.